Currently, numerous clinical trials are evaluating the activity of different drugs in EBV-positive DLBCL cases, including sintilimab, an anti-programmed cell death protein 1 (anti-PD-1) antibody in combination with R-CHOP (NCT: 04181489), a combination of zanubrutinib (Bruton’s tyrosine kinase inhibitor) and anti-PD-1 monoclonal antibody tislelizumab (NCT: 04705129), and a late-phase clinical trial of nanatinostat (class I selective histone deacetylase inhibitor) in combination with the antiviral drug valganciclovir (Nana-val) (NCT: 05011058). This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.